pyrroles has been researched along with Metabolic Diseases in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Arora, S; Bishnoi, M; Chopra, K; Dharavath, RN; Kondepudi, KK | 1 |
| Bousquet, P; Fellmann, L; Monassier, L; Niederhoffer, N; Regnard, P; Weiss, M | 1 |
| Aubertin, G; Benameur, D; Bousquet, P; Choquet, P; Dali-Youcef, N; Greney, H; Monassier, L; Niederhoffer, N; Pons, F; Sigrist, S; Traversi, F; Weiss, M | 1 |
| Athyros, VG; Karagiannis, A; Katsiki, N | 1 |
| Chngrian, GV; Mysyshin, MB; Semegen-Bodak, KV; Slaba, NA; Solomenchuk, TN | 1 |
| Borsini, F; Caprioli, A; Carminati, P; Coccurello, R; Conti, R; Ghirardi, O; Moles, A | 1 |
| Deedwania, P; Singh, V | 1 |
| Boers, GH; The, GK; van de Kerkhof, R; van der Meer, JW | 1 |
| Kamsteeg, J | 1 |
| Both, SP | 1 |
| Lamola, AA | 1 |
| Currier, JS | 1 |
| Chatterjea, JB; Chatterji, AK | 1 |
1 review(s) available for pyrroles and Metabolic Diseases
| Article | Year |
|---|---|
Reducing morbidity and mortality in high risk patients with statins.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Arteriosclerosis; Kidney Failure, Chronic; Metabolic Diseases; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors | 2009 |
12 other study(ies) available for pyrroles and Metabolic Diseases
| Article | Year |
|---|---|
Saroglitazar, a novel dual PPAR-α/γ agonist, reverses high fat-low protein diet-induced metabolic and cognitive aberrations in C57BL/6J male mice.
Topics: Animals; Cognitive Dysfunction; Diet, High-Fat; Diet, Protein-Restricted; Male; Metabolic Diseases; Mice; Mice, Inbred C57BL; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles | 2021 |
Protective effects of the imidazoline-like drug lnp599 in a marmoset model of obesity-induced metabolic disorders.
Topics: Aniline Compounds; Animals; Body Weight; Callithrix; Disease Models, Animal; Imidazolines; Male; Metabolic Diseases; Obesity; Protective Agents; Pyrroles | 2021 |
Effects of imidazoline-like drugs on liver and adipose tissues, and their role in preventing obesity and associated cardio-metabolic disorders.
Topics: Adipose Tissue; Aniline Compounds; Animals; Body Weight; Eating; Hep G2 Cells; Humans; Imidazolines; Liver; Male; Metabolic Diseases; Obesity; Pyrroles; Rats; Rats, Zucker | 2019 |
Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients.
Topics: Age Factors; Amlodipine; Antihypertensive Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Fatty Liver; Heptanoic Acids; Humans; Metabolic Diseases; Non-alcoholic Fatty Liver Disease; Patient Compliance; Pyrroles; Risk; Risk Reduction Behavior | 2013 |
[Proaterogenic metabolic disorders in patients with chronic kidney disease nondiabetic origin: possibility of statin therapy].
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Pressure; Cardiotonic Agents; Disease Progression; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Lipid Metabolism; Male; Metabolic Diseases; Middle Aged; Prognosis; Pyrroles; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2014 |
Olanzapine (LY170053, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine), but not the novel atypical antipsychotic ST2472 (9-piperazin-1-ylpyrrolo[2,1-b][1,3]benzothiazepine), chronic administration induces weight gain, hyperphagia
Topics: Animals; Benzodiazepines; Body Weight; Hyperphagia; Metabolic Diseases; Mice; Olanzapine; Piperazines; Pyrroles; Thiazepines; Weight Gain | 2008 |
[Hemopyrrollactamuria (HPU); from spots to pseudo-disease].
Topics: Humans; Metabolic Diseases; Porphyrias; Pyrroles; Schizophrenia | 2003 |
[Hemopyrrollactamuria (HPU); from spots to pseudo-disease].
Topics: Diagnosis, Differential; Humans; Metabolic Diseases; Porphyrias; Pyrroles | 2003 |
[Hemopyrrollactamuria (HPU); from spots to pseudo-disease].
Topics: Dietary Supplements; Humans; Metabolic Diseases; Porphyrias; Pyrroles | 2003 |
Fluorescence methods in the diagnosis and management of diseases of tetrapyrrole metabolism.
Topics: Bilirubin; Diagnosis, Differential; Humans; Infant, Newborn; Jaundice, Neonatal; Metabolic Diseases; Porphyrias; Protoporphyrins; Pyrroles; Spectrometry, Fluorescence; Tetrapyrroles | 1981 |
How to manage metabolic complications of HIV therapy: what to do while we wait for answers.
Topics: Anabolic Agents; Anti-HIV Agents; Anticholesteremic Agents; Atorvastatin; Exercise Therapy; Gemfibrozil; Growth Hormone; Guidelines as Topic; Heptanoic Acids; HIV Infections; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipodystrophy; Metabolic Diseases; Metformin; Nucleosides; Protease Inhibitors; Pyrroles; Reverse Transcriptase Inhibitors; Risk Factors; Thiazoles; Thiazolidinediones | 2000 |
Porphyrins and porphyrias: new horizons.
Topics: Anemia, Sideroblastic; Heme; India; Metabolic Diseases; Metabolism, Inborn Errors; Porphyrias; Porphyrins; Pyrroles | 1969 |